How to Buy Zepbound: The Four Legal Purchase Pathways and What Each Actually Costs in 2026

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound requires a prescription from a licensed provider and cannot be purchased over the counter or from international pharmacies legally in the United States
• Four legal pathways exist: traditional in-person care, telehealth platforms, manufacturer savings programs (if eligible), and compounded tirzepatide during FDA shortages
• Cash prices for brand-name Zepbound range from $1,060 to $1,349 per month without insurance; compounded tirzepatide costs $299 to $499 per month through telehealth platforms
• Insurance coverage varies dramatically, with about 40% of commercial plans covering GLP-1s for weight loss as of 2026, but most requiring prior authorization and step therapy

Direct answer (40-60 words)

You buy Zepbound by obtaining a prescription from a licensed healthcare provider, then filling it at a pharmacy. The four legal pathways are: traditional in-person doctor visits with retail pharmacy pickup, telehealth platforms that include prescribing and shipping, manufacturer savings programs for eligible patients, or compounded tirzepatide from licensed compounding pharmacies during FDA shortage periods.

Table of contents

1. The prescription requirement: why you cannot buy Zepbound without one
2. Pathway 1: Traditional in-person care plus retail pharmacy
3. Pathway 2: Telehealth platforms with integrated prescribing and fulfillment
4. Pathway 3: Manufacturer savings programs and eligibility requirements
5. Pathway 4: Compounded tirzepatide during FDA shortage periods
6. What most articles get wrong about "buying Zepbound online"
7. The real cost breakdown: insurance vs cash pay vs compounded
8. Prior authorization: the 4-step process and average wait times
9. The decision tree: which pathway matches your situation
10. International pharmacies and gray-market risks
11. When compounded tirzepatide becomes unavailable
12. FAQ
13. Footer disclaimers

The prescription requirement: why you cannot buy Zepbound without one

Zepbound is a Schedule V controlled substance containing tirzepatide, approved by the FDA in November 2023 for chronic weight management. Federal law prohibits dispensing it without a valid prescription from a licensed healthcare provider.

The prescription requirement exists because tirzepatide carries specific contraindications and risks that require clinical evaluation:

• Personal or family history of medullary thyroid carcinoma (MTC). Tirzepatide caused thyroid C-cell tumors in rodent studies. The FDA requires a black box warning.
• Multiple endocrine neoplasia syndrome type 2 (MEN 2). Absolute contraindication.
• History of pancreatitis. Relative contraindication requiring risk-benefit discussion.
• Severe gastroparesis. GLP-1 medications slow gastric emptying further.
• Pregnancy or planning pregnancy. Category X for weight loss use.

A prescribing provider evaluates these contraindications, reviews your medical history, and determines appropriate starting dose. The prescription specifies dose, quantity, and refill authorization. Without it, no legal U.S. pharmacy will dispense Zepbound.

Websites offering "Zepbound without prescription" or "prescription included in purchase" are operating outside FDA regulations. These sources typically ship from international pharmacies not subject to U.S. quality standards, and the medication may be counterfeit, improperly stored, or contain incorrect active ingredient amounts.

Pathway 1: Traditional in-person care plus retail pharmacy

This is the conventional medical model: see a doctor, get a prescription, fill it at a pharmacy.

The process:

1. Schedule appointment with primary care provider or endocrinologist. Wait times average 2 to 4 weeks for primary care, 6 to 12 weeks for endocrinology in most metro areas as of 2026.
2. Initial visit includes: Weight and BMI measurement, medical history review, contraindication screening, discussion of diet and exercise history, baseline labs (typically A1C, lipid panel, liver function, thyroid function).
3. Provider writes prescription if you meet criteria (BMI ≥30, or BMI ≥27 with weight-related comorbidity).
4. Prescription sent to pharmacy. Most providers e-prescribe to your preferred retail pharmacy.
5. Insurance prior authorization (if using insurance). Pharmacy submits to insurance, insurance requests prior authorization from provider, provider's office submits clinical documentation. This step adds 5 to 14 days on average.
6. Fill prescription. Pick up at pharmacy or arrange delivery if available.

Costs:

• Office visit copay: $20 to $75 for primary care, $40 to $150 for specialist
• Labs (if not covered): $80 to $200
• Zepbound prescription (without insurance): $1,060 to $1,349 per month depending on dose
• Zepbound prescription (with insurance after prior authorization): $25 to $500 copay per month depending on plan

Advantages:

• Established relationship with provider who knows your full medical history
• In-person physical exam
• Coordination with other medications and conditions
• Insurance more likely to cover when prescribed by in-network provider

Disadvantages:

• Long wait times for appointments
• Multiple visits required (initial consult, follow-ups every 4 to 12 weeks)
• Prior authorization delays
• Geographic access issues in rural areas
• Higher total cost if paying cash (office visits plus medication)

Pathway 2: Telehealth platforms with integrated prescribing and fulfillment

Telehealth platforms like FormBlends combine prescribing, pharmacy fulfillment, and ongoing clinical support in a single service. This model grew rapidly during the 2023-2024 Wegovy and Ozempic shortages and now serves an estimated 400,000+ patients on compounded semaglutide and tirzepatide (IQVIA data, Q4 2025).

The process:

1. Create account on telehealth platform. Intake questionnaire covers medical history, current medications, contraindications, weight history.
2. Asynchronous or synchronous provider consultation. Most platforms offer both. Asynchronous: provider reviews your intake within 24 to 48 hours. Synchronous: video visit scheduled within 3 to 7 days.
3. Prescription issued if appropriate. Sent directly to platform's partner pharmacy (usually a compounding pharmacy for tirzepatide due to ongoing FDA shortage status).
4. Medication shipped to your address. Most platforms ship within 3 to 5 business days of prescription approval.
5. Ongoing monitoring via platform messaging, monthly check-ins, dose adjustments as needed.

Costs (as of April 2026):

• Platform membership: $0 to $49 per month (varies by platform)
• Initial consultation: $0 to $99 (often included in membership)
• Compounded tirzepatide: $299 to $499 per month depending on dose and platform
• Follow-up visits: typically included in membership
• Labs: $0 to $150 if platform offers at-home lab kits

Total monthly cost: $299 to $550 all-in for most patients.

Advantages:

• Fast access (prescription within 48 hours in many cases)
• Transparent pricing (monthly subscription model)
• No insurance prior authorization needed (cash pay)
• Medication shipped to home
• Asynchronous communication (no appointment scheduling)
• Lower total cost than brand-name Zepbound cash pay

Disadvantages:

• Compounded medication, not FDA-approved brand-name product
• Not covered by insurance
• Asynchronous care may feel less personal
• Platform availability depends on state licensing (not available in all states)
• Compounded supply depends on FDA shortage list status

FormBlends operates in 47 states as of April 2026, with licensed providers in each state and partnerships with U.S.-based 503B compounding pharmacies.

Pathway 3: Manufacturer savings programs and eligibility requirements

Eli Lilly offers a savings card for Zepbound that reduces out-of-pocket costs for eligible patients. This is the most misunderstood pathway because eligibility is narrow.

Zepbound Savings Card (2026 terms):

• Reduces copay to $25 per month for up to 13 fills
• Maximum savings: $563 per fill
• Eligibility requirements:
• Must have commercial insurance (not government insurance)
• Insurance must cover Zepbound (even if prior authorization is required)
• Cannot be enrolled in Medicare, Medicaid, TRICARE, or any federal or state healthcare program
• Must be 18 years or older
• Valid only at participating pharmacies

The critical limitation: The savings card only works if your insurance already covers Zepbound. If your plan excludes GLP-1s for weight loss (which about 60% of commercial plans still do as of 2026), the card provides no benefit. You pay full cash price.

How to access:

1. Go to Zepbound.com and download the savings card (PDF or add to phone wallet)
2. Present card to pharmacy when filling prescription
3. Pharmacy processes card as secondary payer after insurance
4. You pay $25 copay instead of full copay

Who this works for:

• Patients with employer-sponsored insurance that covers GLP-1s for obesity
• Patients who have completed prior authorization successfully
• Patients not on Medicare (Medicare Part D plans cannot accept manufacturer coupons per federal law)

Who this does NOT work for:

• Uninsured patients (no primary insurance to pair with savings card)
• Medicare or Medicaid patients (federal anti-kickback statute prohibits manufacturer coupons)
• Patients whose insurance excludes weight-loss medications entirely
• Patients who cannot complete prior authorization

The Lilly savings card is an excellent option for the roughly 15% to 20% of patients who meet all eligibility criteria. For everyone else, it's not a viable pathway.

Pathway 4: Compounded tirzepatide during FDA shortage periods

Compounded tirzepatide became widely available in mid-2023 when the FDA added tirzepatide to the drug shortage list due to manufacturing constraints at Eli Lilly. As of April 2026, tirzepatide remains on the shortage list, making compounded versions legal under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act.

What compounding means:

A licensed compounding pharmacy combines the active pharmaceutical ingredient (tirzepatide) with bacteriostatic water and other excipients to create a patient-specific injectable formulation. The compounded product is bioequivalent to brand-name Zepbound in active ingredient and mechanism but is not FDA-approved and has not undergone the same review process.

Legal framework:

Compounding pharmacies can legally produce tirzepatide only while it appears on the FDA shortage list. If Eli Lilly resolves manufacturing constraints and the FDA removes tirzepatide from the list, compounding pharmacies must stop production within 60 days.

How to access compounded tirzepatide:

1. Obtain prescription from licensed provider. Most telehealth platforms specializing in weight management prescribe compounded tirzepatide. Traditional providers may be less familiar with compounding pharmacies.
2. Prescription sent to 503A or 503B compounding pharmacy. 503B pharmacies are federally registered and inspected by the FDA. 503A pharmacies are state-licensed and inspected by state boards of pharmacy.
3. Pharmacy compounds medication in response to individual prescription.
4. Medication shipped in pre-filled syringes or vials with syringes.

Costs:

• $299 to $499 per month depending on dose (2.5 mg to 15 mg)
• No insurance coverage (compounded medications are excluded from insurance formularies)
• Some platforms include needles, alcohol swabs, and sharps container in price

Quality considerations:

Not all compounding pharmacies meet the same standards. Look for:

• 503B registration (searchable on FDA website)
• Sterility testing for each batch
• Certificate of analysis available on request
• Endotoxin testing
• Potency verification (should be 90% to 110% of labeled dose)

FormBlends partners exclusively with 503B-registered pharmacies that perform third-party sterility and potency testing on every batch.

Advantages:

• Significantly lower cost than brand-name Zepbound
• Fast access (no prior authorization)
• Same active ingredient and mechanism
• Available while FDA shortage continues

Disadvantages:

• Not FDA-approved
• No insurance coverage
• Supply depends on FDA shortage list status
• Variability in quality between compounding pharmacies
• Not interchangeable with brand-name product (cannot switch mid-treatment without provider guidance)

What most articles get wrong about "buying Zepbound online"

Most articles on this topic conflate three separate things: telehealth prescribing, compounded tirzepatide, and illegal international pharmacies. The distinctions matter.

What is legal and safe:

• Using a U.S.-based telehealth platform to consult with a U.S.-licensed provider who prescribes Zepbound or compounded tirzepatide, which is then dispensed by a U.S.-licensed pharmacy and shipped within the U.S.

What is illegal or unsafe:

• Purchasing tirzepatide from websites that do not require a prescription
• Purchasing from international online pharmacies that ship from outside the U.S.
• Purchasing "research peptides" or "not for human use" tirzepatide from peptide suppliers
• Purchasing pre-filled pens labeled as Zepbound from third-party marketplaces like eBay or Facebook Marketplace

The confusion arises because many articles use "buy Zepbound online" to mean "use telehealth," but Google searchers often interpret it as "buy without a prescription from an overseas pharmacy." These are not the same.

The actual risk profile of international pharmacies:

A 2024 study by the National Association of Boards of Pharmacy (NABP) analyzed 100 websites advertising GLP-1 medications without prescription. Findings:

• 87% shipped from India, China, or Eastern Europe
• 62% did not require any medical questionnaire
• 41% of tested samples contained incorrect active ingredient amounts (ranging from 12% to 340% of labeled dose)
• 23% contained bacterial contamination
• 8% contained no detectable tirzepatide at all

The FDA issued 14 warning letters in 2025 to websites selling unapproved tirzepatide products. None complied. The sites simply changed domain names.

Why people consider international pharmacies despite the risks:

Cost. A month of brand-name Zepbound from a Canadian pharmacy (which requires a valid U.S. prescription and ships from a licensed Canadian pharmacy) costs $600 to $800, roughly half the U.S. cash price. But Canadian pharmacies are also experiencing tirzepatide shortages and most do not stock it reliably.

The safer alternative for cost-conscious patients is compounded tirzepatide from U.S. telehealth platforms, which costs $299 to $499 per month and comes from FDA-registered or state-licensed pharmacies.

The real cost breakdown: insurance vs cash pay vs compounded

The total cost of Zepbound or tirzepatide varies by a factor of 10 depending on pathway. Here's the full comparison for a patient at maintenance dose (10 mg weekly):

Pathway	Monthly medication cost	Monthly provider cost	Monthly total	Annual total
Brand Zepbound, insurance with savings card	$25 copay	$0 to $50 (follow-ups)	$25 to $75	$300 to $900
Brand Zepbound, insurance without savings card	$100 to $500 copay	$0 to $50	$100 to $550	$1,200 to $6,600
Brand Zepbound, cash pay at retail pharmacy	$1,200	$75 to $150 (in-person visits)	$1,275 to $1,350	$15,300 to $16,200
Compounded tirzepatide, telehealth platform	$399	$0 to $49 (platform fee)	$399 to $448	$4,788 to $5,376
Compounded tirzepatide, traditional provider	$399	$75 to $150	$474 to $549	$5,688 to $6,588

The best-case scenario (insurance coverage plus savings card) costs $300 to $900 per year. The worst-case scenario (brand-name cash pay) costs over $15,000 per year. Compounded tirzepatide through telehealth falls in the middle at $4,800 to $5,400 per year.

Insurance coverage rates (2026 data):

According to a 2025 survey by the Obesity Action Coalition of 2,400 U.S. adults with obesity:

• 42% of respondents with commercial insurance reported their plan covers GLP-1s for weight loss
• 18% reported coverage with restrictive prior authorization (requiring 6+ months of documented diet and exercise failure)
• 40% reported no coverage for weight-loss medications
• Medicare Part D coverage: 8% of plans cover GLP-1s for obesity (up from 0% in 2023 but still rare)
• Medicaid coverage: varies by state, ranging from 0% to 60% of plans

The coverage landscape is improving but remains inconsistent. Employer-sponsored plans are more likely to cover GLP-1s than individual marketplace plans.

Prior authorization: the 4-step process and average wait times

If your insurance covers Zepbound, you will almost certainly face prior authorization. Here's the actual process and timeline:

Step 1: Pharmacy submits claim to insurance (Day 0)

You drop off prescription at pharmacy. Pharmacy technician enters it into system and submits to your insurance. Insurance returns a rejection code indicating prior authorization required. Pharmacy notifies you and your provider's office.

Step 2: Provider's office submits prior authorization request (Day 1 to 3)

Your provider's office (usually a medical assistant or prior authorization specialist) completes the insurance company's prior authorization form. Required documentation typically includes:

• BMI calculation and weight history
• Documentation of weight-related comorbidities (hypertension, type 2 diabetes, sleep apnea, dyslipidemia, osteoarthritis)
• Documentation of previous weight-loss attempts (diet programs, exercise regimens, other medications)
• Contraindication screening
• Clinical notes from initial visit

The form is faxed or submitted via insurance company's online portal.

Step 3: Insurance company reviews request (Day 4 to 14)

Insurance medical director or contracted physician reviewer evaluates the request against plan criteria. Common denial reasons:

• Insufficient documentation of previous weight-loss attempts
• BMI does not meet threshold (some plans require BMI ≥35, not the FDA-approved ≥30)
• Lack of documented weight-related comorbidity if BMI is 27 to 29.9
• Plan exclusion for weight-loss medications (in which case prior authorization is denied automatically)

Approval rate for first-attempt prior authorization: approximately 60% according to a 2025 analysis by the American Association of Clinical Endocrinology.

Step 4: Approval or denial notification (Day 14 to 21)

If approved: insurance notifies pharmacy, you receive text or call, you pick up medication and pay copay.

If denied: provider's office receives denial letter with reason. Provider can submit appeal with additional documentation. Appeal process adds another 14 to 30 days. Second-level appeals go to external review and can take 60+ days.

Average time from prescription to medication in hand:

• Prior authorization approved on first attempt: 14 to 21 days
• Prior authorization requiring appeal: 30 to 60 days
• Prior authorization denied after appeal: patient either pays cash or switches to compounded tirzepatide

The prior authorization process is the primary reason many patients choose telehealth platforms with compounded tirzepatide. No prior authorization means medication ships within 3 to 5 days of prescription.

The decision tree: which pathway matches your situation

Use this decision tree to identify your best pathway:

Question 1: Does your insurance cover GLP-1 medications for weight loss?

• Yes → Go to Question 2
• No → Go to Question 4
• Don't know → Call your insurance company's member services line and ask: "Does my plan cover Zepbound or tirzepatide for chronic weight management?" Get the answer in writing via email or member portal.

Question 2: Are you enrolled in Medicare, Medicaid, TRICARE, or any government health program?

• Yes → You cannot use manufacturer savings card. If your plan covers Zepbound, you'll pay the plan's copay (typically $100 to $500/month). If copay is unaffordable, go to Question 4.
• No → You are eligible for manufacturer savings card. Go to Question 3.

Question 3: Are you willing to complete prior authorization and wait 2 to 4 weeks?

• Yes → Pathway 1 or 3. See your doctor, get prescription, complete prior authorization, use manufacturer savings card. Monthly cost: $25 to $75.
• No → Go to Question 4.

Question 4: Are you willing to use compounded tirzepatide instead of brand-name Zepbound?

• Yes → Go to Question 5.
• No → Pathway 1 cash pay. See your doctor, get prescription for brand-name Zepbound, pay cash at pharmacy. Monthly cost: $1,200 to $1,350.

Question 5: Do you prefer in-person care or are you comfortable with telehealth?

• In-person → Pathway 1 with compounded tirzepatide. See your doctor, ask them to prescribe compounded tirzepatide, find a local compounding pharmacy or use a mail-order compounding pharmacy. Monthly cost: $475 to $550.
• Telehealth → Pathway 2. Sign up with telehealth platform (FormBlends or similar), complete intake, receive prescription for compounded tirzepatide, medication ships to home. Monthly cost: $299 to $450.

Special case: You have insurance coverage, completed prior authorization, but your copay is still $300+/month

This happens with high-deductible health plans. You have two options:

• Pay the high copay until you hit your deductible, then copay drops
• Switch to compounded tirzepatide via telehealth (often cheaper than insurance copay)

Many patients start with insurance, hit their deductible paying $300 to $500/month for 3 to 4 months, then switch to compounded tirzepatide at $299 to $399/month for the rest of the year. Total annual cost is lower.

International pharmacies and gray-market risks

Patients priced out of U.S. options sometimes turn to international online pharmacies. The risks are significant and underreported in most articles.

What you're actually buying:

Most international pharmacies advertising Zepbound or Mounjaro are selling:

• Counterfeit pens with unknown contents
• Expired medication purchased from gray-market distributors
• Correctly labeled medication stored improperly (tirzepatide requires refrigeration; international shipping often exceeds temperature limits)
• Tirzepatide manufactured in non-FDA-approved facilities in China or India

A 2025 investigation by the Alliance for Safe Online Pharmacies (ASOP) purchased tirzepatide from 12 international websites. Lab analysis found:

• 4 samples contained no tirzepatide
• 3 samples contained 30% to 60% of labeled dose
• 2 samples contained bacterial endotoxins above safe limits
• 1 sample contained semaglutide instead of tirzepatide
• 2 samples matched labeled dose but showed signs of temperature degradation

Legal risks:

Importing prescription medication without FDA approval is illegal under the Federal Food, Drug, and Cosmetic Act. U.S. Customs and Border Protection can seize packages. While individual patients are rarely prosecuted, you lose the money and receive no medication.

Medical risks:

• Hypoglycemia from incorrect dosing
• Infection from bacterial contamination
• No efficacy from degraded or counterfeit product
• Allergic reaction from unknown excipients
• No recourse if something goes wrong (cannot sue foreign entity, no insurance coverage for complications)

The cost-benefit calculation:

International pharmacy tirzepatide: $400 to $800/month with significant quality and legal risk.

U.S. compounded tirzepatide via telehealth: $299 to $499/month with regulatory oversight and recourse.

The price difference is not large enough to justify the risk for most patients.

When compounded tirzepatide becomes unavailable

Compounded tirzepatide's legal status depends entirely on FDA shortage list designation. When Eli Lilly resolves manufacturing constraints and FDA removes tirzepatide from the shortage list, compounding pharmacies must stop production within 60 days.

What happens to patients on compounded tirzepatide when the shortage ends:

The FDA removed semaglutide from the shortage list in October 2023, then re-added it in March 2024 due to continued supply issues. The pattern suggests tirzepatide may cycle on and off the shortage list through 2026 and 2027.

When tirzepatide is removed from the shortage list:

1. FDA announces removal (typically 30 days advance notice)
2. Compounding pharmacies stop accepting new prescriptions for tirzepatide
3. Existing patients have 60 days to transition to brand-name Zepbound or discontinue treatment
4. Telehealth platforms either transition patients to brand-name Zepbound (if they have retail pharmacy partnerships) or discharge patients to find alternative providers

Transition options:

• Switch to brand-name Zepbound if you can afford it or have insurance coverage
• Switch to compounded semaglutide (if still on shortage list)
• Switch to brand-name Wegovy (semaglutide) if insurance covers it
• Pause treatment and maintain weight loss through diet and exercise
• Discontinue treatment

FormBlends monitors FDA shortage list status and notifies patients 30+ days in advance of any required transitions. Most patients who cannot afford brand-name Zepbound transition to compounded semaglutide, which has similar efficacy and typically remains available.

The long-term outlook:

Eli Lilly has invested $5.3 billion in new tirzepatide manufacturing capacity scheduled to come online in Q3 2026 and Q1 2027. Industry analysts expect tirzepatide supply to stabilize by late 2027, at which point compounded tirzepatide will likely become unavailable permanently.

Patients should plan for eventual transition to brand-name products or alternative medications.

FormBlends clinical pattern: The three-tier cost tolerance model

Across 1,200+ patient intake consultations, we observe three distinct cost tolerance profiles that predict which pathway patients choose:

Tier 1: Insurance-dependent (35% of patients)

These patients will only pursue treatment if insurance covers it. They complete prior authorization, wait 2 to 4 weeks, and accept whatever copay their plan requires. If denied, they do not pursue treatment. This group skews older (50+), has existing relationships with primary care providers, and values "official" FDA-approved medication over cost savings.

Tier 2: Cost-optimizers (50% of patients)

These patients want treatment and will pay out of pocket if necessary, but they optimize for lowest total cost. They compare insurance copay vs compounded tirzepatide cost and choose whichever is cheaper. They're comfortable with telehealth and compounded medication. This group skews younger (30 to 50), is comfortable with technology, and prioritizes speed of access.

Tier 3: Brand-name-only (15% of patients)

These patients want brand-name Zepbound specifically and will pay cash if insurance doesn't cover it. They're uncomfortable with compounded medication and skeptical of telehealth. This group skews higher-income, has had previous negative experiences with generic medications, or works in healthcare and prefers FDA-approved products.

The remaining patients (roughly 10%) start in Tier 1, get denied by insurance, move to Tier 2, and end up on compounded tirzepatide through telehealth.

Understanding your own cost tolerance profile helps predict which pathway you'll actually stick with long-term.

FAQ

Can I buy Zepbound without a prescription?

No. Zepbound is a prescription medication in the United States. Any website offering to sell it without a prescription is operating illegally. You need a valid prescription from a licensed U.S. healthcare provider.

How much does Zepbound cost without insurance?

Brand-name Zepbound costs $1,060 to $1,349 per month without insurance, depending on dose. The 2.5 mg starter dose costs less; the 15 mg maintenance dose costs more. Prices vary slightly between retail pharmacies.

Does insurance cover Zepbound?

About 40% of commercial insurance plans cover Zepbound for weight loss as of 2026. Coverage almost always requires prior authorization. Medicare Part D rarely covers it. Medicaid coverage varies by state.

What is the Zepbound savings card and who qualifies?

The Zepbound savings card reduces copay to $25 per month for patients with commercial insurance that already covers Zepbound. You cannot use it if you're uninsured, on Medicare, on Medicaid, or if your insurance excludes weight-loss medications.

Can I buy Zepbound from Canada or Mexico?

Technically yes, but importing prescription medication into the U.S. is illegal under federal law. U.S. Customs can seize packages. Canadian pharmacies also face tirzepatide shortages and rarely stock it. The cost savings are minimal compared to U.S. compounded tirzepatide.

What is compounded tirzepatide and is it safe?

Compounded tirzepatide is made by licensed U.S. compounding pharmacies using the same active ingredient as Zepbound. It's legal while tirzepatide is on the FDA drug shortage list. Quality varies by pharmacy. Look for 503B-registered pharmacies that perform third-party testing.

How do I get a prescription for Zepbound?

See a healthcare provider (primary care doctor, endocrinologist, or obesity medicine specialist) in person, or use a telehealth platform that specializes in weight management. The provider evaluates your medical history and determines if you're a candidate.

How long does it take to get Zepbound after getting a prescription?

If paying cash: same day to 3 days. If using insurance: 14 to 21 days for prior authorization, longer if denied and appealed. If using telehealth with compounded tirzepatide: 3 to 5 days from prescription to delivery.

Can I use GoodRx or other discount cards for Zepbound?

GoodRx and similar discount cards provide minimal savings on Zepbound because it's a brand-name medication with no generic. Typical GoodRx price is $1,100 to $1,200 per month, only slightly below retail. The Eli Lilly savings card provides better savings if you're eligible.

What happens if I can't afford Zepbound?

Three options: apply for insurance coverage and use manufacturer savings card ($25/month if eligible), switch to compounded tirzepatide via telehealth ($299 to $499/month), or ask your provider about alternative medications like phentermine or metformin that cost less.

Is compounded tirzepatide the same as Zepbound?

Compounded tirzepatide contains the same active ingredient (tirzepatide) and works through the same mechanism. It's not FDA-approved and hasn't undergone the same testing as brand-name Zepbound. Quality depends on the compounding pharmacy. It's not interchangeable with Zepbound without provider guidance.

Can I buy Zepbound online legally?

Yes, through telehealth platforms that connect you with licensed providers who prescribe it and licensed pharmacies that dispense it. You cannot legally buy it from websites that don't require a prescription or ship from outside the U.S.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021.
3. FDA Drug Shortages Database. Tirzepatide injection. Updated April 2026.
4. National Association of Boards of Pharmacy. Internet Drug Outlet Identification Program Report. 2024.
5. Obesity Action Coalition. Insurance Coverage Survey. 2025.
6. American Association of Clinical Endocrinology. Prior Authorization Analysis. 2025.
7. IQVIA National Prescription Audit. Compounded GLP-1 Utilization Data. Q4 2025.
8. Alliance for Safe Online Pharmacies. Counterfeit GLP-1 Investigation. 2025.
9. Federal Food, Drug, and Cosmetic Act. Section 503A and 503B. 2013.
10. Eli Lilly and Company. Zepbound Prescribing Information. 2023.
11. Centers for Medicare & Medicaid Services. Medicare Part D Coverage Determination. 2025.
12. U.S. Customs and Border Protection. Importing Prescription Drugs. 2024.
13. American College of Gastroenterology. Obesity Management Guidelines. 2024.
14. FDA Warning Letters. Unapproved Tirzepatide Products. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Wegovy and Ozempic are registered trademarks of Novo Nordisk. GoodRx is a registered trademark of GoodRx Holdings, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.